Neutralising antibodies against human metapneumovirus

Lei Guo; Li Li; Li Liu; Tiesong Zhang; Ming Sun

doi:10.1016/S2666-5247(23)00134-9

Neutralising antibodies against human metapneumovirus

Lancet Microbe. 2023 Sep;4(9):e732-e744. doi: 10.1016/S2666-5247(23)00134-9. Epub 2023 Jul 24.

Authors

Lei Guo¹, Li Li¹, Li Liu¹, Tiesong Zhang², Ming Sun³

Affiliations

¹ Yunnan Key Laboratory of Children's Major Disease Research, Yunnan Institute of Pediatrics, Kunming Children's Hospital, Kunming, Yunnan, China.
² Yunnan Key Laboratory of Children's Major Disease Research, Yunnan Institute of Pediatrics, Kunming Children's Hospital, Kunming, Yunnan, China. Electronic address: zhangtiesong@crhealthcare.com.hk.
³ Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, Yunnan, China. Electronic address: sunming@imbcams.com.cn.

PMID: 37499668
DOI: 10.1016/S2666-5247(23)00134-9

Abstract

Human metapneumovirus (hMPV) is one of the leading causes of respiratory infection. Since its discovery in 2001, no specific antiviral or vaccine has been available in contrast to its closely related family member human respiratory syncytial virus (hRSV). Neutralising monoclonal antibodies (nMAbs) are the core effectors of vaccines and are essential therapeutic immune drugs against infectious pathogens. The development of nMAbs against hMPV has accelerated in recent years as a result of breakthroughs in viral fusion (F) protein structural biology and experience with hRSV and other enveloped viruses. We provide an overview of the potent F-specific nMAbs of hMPV, generalise their targeting F antigen epitopes, and discuss the nMAb development strategy and future directions for hMPV and broad-spectrum hMPV, hRSV nMabs, and vaccine research and development.

Publication types

Review